MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
9.45
+0.17 (1.83%)
Oct 19, 2026, 4:00 PM EDT - Market closed
MeiraGTx Holdings Revenue
MeiraGTx Holdings had revenue of $321.43M in the quarter ending June 30, 2026, with 8,608.59% growth. This brings the company's total for the last twelve months to $397.50M, up 948.35% year-over-year. In the year 2025, MeiraGTx Holdings had annual revenue of $81.39M with 144.57% growth. That makes MeiraGTx Holdings the 12,588th largest company in the world by revenue and 2,440th in the United States.
Revenue (ttm)
$397.50M
Revenue Growth
+948.35%
P/S Ratio
2.28
Revenue / Employee
$1,011,453
Employees
393
Market Cap
907.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 81.39M | 48.11M | 144.57% |
| Dec 31, 2024 | 33.28M | 19.26M | 137.42% |
| Dec 31, 2023 | 14.02M | -1.90M | -11.95% |
| Dec 31, 2022 | 15.92M | -21.78M | -57.77% |
| Dec 31, 2021 | 37.70M | 22.14M | 142.25% |
| Dec 31, 2020 | 15.56M | 2.27M | 17.09% |
| Dec 31, 2019 | 13.29M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 276.79M |
| Arbutus Biopharma | 181.72M |
| Immatics | 47.65M |
| Monte Rosa Therapeutics | 28.73M |
| Aktis Oncology | 10.06M |
| SL Science Holding | 3.27M |
MGTX News
- 25 days ago - MeiraGTx initiated with a Neutral at Goldman Sachs - TheFly
- 26 days ago - MeiraGTx appoints Sebulsky to its Board of Directors - TheFly
- 26 days ago - MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors - GlobeNewsWire
- 7 weeks ago - Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical - PRNewsWire
- 2 months ago - MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - GlobeNewsWire
- 2 months ago - MeiraGTx Holdings Earnings release: Q2 2026 - Filings
- 2 months ago - MeiraGTx Holdings Quarterly report: Q2 2026 - Filings
- 2 months ago - MeiraGTx Holdings Slides: Corporate presentation - Filings